VERV and LLY Related Headlines
Go Back- Lilly completes Verve Therapeutics acquisition for cardiovascular treatments
- Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
- Lilly tender offer for Verve expires with 55.7% of shares tendered
- Lilly and Verve announce expiration of Verve tender offer
- Prime Medicine stock soars amid gene editing sector momentum
- BMO Capital Downgrades Verve Therapeutics (VERV) to Market Perform
- Eli Lilly and Verve's gene-editing M&A deal 'an important milestone' - Citizens JMP
- Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
- Eli Lilly & Co. (LLY) to acquire Verve Therapeutics (VERV) for $10.50/sh Cash plus CVR
- Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
- Eli Lilly & Co. (LLY) In Advanced Talks To Buy Verve For Up To $1.3bln- FT
VERV and LLY Related Press Releases
Go Back- Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
- Lilly and Verve announce expiration of Verve tender offer
- Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
